28% Lower Recurrence Risk with KEYTRUDA and WELIREG Combo Marks Turning Point for Early-Stage Kidney Cancer
First Positive Phase 3 Data for HIF-2a Inhibitor & Immunotherapy in Early-Stage RCC
In a development poised to redefine treatment for certain kidney cancer patients, Merck's KEYTRUDA (pembrolizumab) plus WELIREG (belzutifan) demonstrated a 28% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone in earlier-stage renal cell carcinoma (RCC) patients following nephrectomy. These results, from the pivotal Phase 3 LITESPARK-022 trial, represent the first-ever positive data for a HIF-2a inhibitor combined with immunotherapy in early-stage disease, making this a potential new standard of care.
Clinical Impact: Combination Outperforms Standard Adjuvant Therapy
The trial enrolled 1,841 patients with clear cell RCC and randomized them to receive either WELIREG plus KEYTRUDA or KEYTRUDA plus placebo as adjuvant therapy after surgery. At a median follow-up of 28.4 months, the hazard ratio for disease-free survival (DFS) was 0.72 (95% CI: 0.59–0.87; p=0.0003) favoring the combination. The estimated 24-month DFS rate reached 80.7% for the combination arm versus 73.7% for monotherapy—a meaningful improvement for patients battling risk of recurrence after nephrectomy.
| Arm | 24-Month DFS Rate (%) | Hazard Ratio for Recurrence or Death | Grade =3 Adverse Events (%) |
|---|---|---|---|
| KEYTRUDA + WELIREG | 80.7% | 0.72 | 52.1% |
| KEYTRUDA + Placebo | 73.7% | N/A | 30.2% |
Regulatory Outlook: FDA Priority Review Set for June 2026
With these robust results, the U.S. FDA has accepted for priority review the supplemental New Drug Application (sNDA) for WELIREG in combination with KEYTRUDA for adjuvant treatment in certain RCC patients. A Prescription Drug User Fee Act (PDUFA) target date is set for June 19, 2026. Merck is also in active discussions with global regulators, signaling the intent to make this regimen available widely, pending further approvals.
Safety Profile: Higher Rates of Anemia and ALT Elevation in Combo Arm
The safety profile of the combination was largely consistent with what’s previously observed for each drug, although higher rates of grade =3 treatment-emergent adverse events (TEAEs) were noted. The most common serious side effects included anemia (12.1%), elevated ALT (6.4%), and hypoxia (4.6%) in the combination arm. Importantly, grade 5 (fatal) TEAEs occurred at similar low rates in both groups (1.1% vs 1.2%).
Potential to Reshape Clinical Practice and Address High-Risk Early RCC
Experts note that about 40% of RCC patients face recurrence risk after initial treatment. The combination of a HIF-2a inhibitor with immunotherapy, demonstrated here for the first time, offers new hope for extending recurrence-free survival. Merck has already positioned its program at the forefront of RCC care, with more than 50 ongoing trials and a broad global footprint for KEYTRUDA and WELIREG across different cancer settings.
Key Takeaways for Physicians and Investors
- This is the first Phase 3 trial to show a statistically significant DFS benefit of a HIF-2a inhibitor plus immunotherapy combo in early RCC.
- KEYTRUDA and WELIREG could soon become a new adjuvant standard for patients with clear cell RCC at increased risk post-nephrectomy, pending regulatory outcomes.
- Physicians should consider the higher risk for grade =3 anemia and elevated liver enzymes in treatment planning.
- FDA decision, set for mid-2026, could unlock a high-value new market for Merck's oncology portfolio.
What’s Next?
The LITESPARK-022 trial will continue to monitor overall survival (OS), a key secondary endpoint, and Merck is actively communicating with regulators worldwide. As adjuvant therapies gain traction in oncology, this new combination may signal a notable shift for both patients and investors tracking Merck’s momentum in solid tumor oncology.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI